144 related articles for article (PubMed ID: 17162129)
1. Expression of Bax, p53, and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis.
Karlidag T; Cobanoglu B; Keles E; Alpay HC; Ozercan I; Kaygusuz I; Yalcin S; Sakallioglu O
Am J Otolaryngol; 2007; 28(1):31-6. PubMed ID: 17162129
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Yu XM; Lo CY; Chan WF; Lam KY; Leung P; Luk JM
Clin Cancer Res; 2005 Nov; 11(22):8063-9. PubMed ID: 16299237
[TBL] [Abstract][Full Text] [Related]
3. Expression of cell-cycle regulators (cyclin D1, cyclin E, p27kip1, p57kip2) in papillary thyroid carcinoma.
Lee SH; Lee JK; Jin SM; Lee KC; Sohn JH; Chae SW; Kim DH
Otolaryngol Head Neck Surg; 2010 Mar; 142(3):332-7. PubMed ID: 20172376
[TBL] [Abstract][Full Text] [Related]
4. Maspin in thyroid cancer: its relationship with p53 and clinical outcome.
Boltze C; Schneider-Stock R; Meyer F; Peters B; Quednow C; Hoang-Vu C; Roessner A
Oncol Rep; 2003; 10(6):1783-7. PubMed ID: 14534696
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical characteristics of diffuse sclerosing variant of papillary carcinoma: comparison with conventional papillary carcinoma.
Koo JS; Shin E; Hong SW
APMIS; 2010 Oct; 118(10):744-52. PubMed ID: 20854468
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator activated receptor gamma immunohistochemical expression in human papillary thyroid carcinoma tissues. Possible relationship to lymph node metastasis.
Galusca B; Dumollard JM; Chambonniere ML; Germain N; Prades JM; Péoc'h M; Estour B
Anticancer Res; 2004; 24(3b):1993-7. PubMed ID: 15274390
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer.
Melck A; Masoudi H; Griffith OL; Rajput A; Wilkins G; Bugis S; Jones SJ; Wiseman SM
Ann Surg Oncol; 2007 Dec; 14(12):3403-11. PubMed ID: 17882495
[TBL] [Abstract][Full Text] [Related]
9. In situ detection of hTERT mRNA relates to Ki-67 labeling index in papillary thyroid carcinoma.
Chou SJ; Chen CM; Harn HJ; Chen CJ; Liu YC
J Surg Res; 2001 Jul; 99(1):75-83. PubMed ID: 11421607
[TBL] [Abstract][Full Text] [Related]
10. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
11. p27kip1 expression distinguishes papillary hyperplasia in Graves' disease from papillary thyroid carcinoma.
Erickson LA; Yousef OM; Jin L; Lohse CM; Pankratz VS; Lloyd RV
Mod Pathol; 2000 Sep; 13(9):1014-9. PubMed ID: 11007042
[TBL] [Abstract][Full Text] [Related]
12. [Expression of mucin-l and beta-catenin in papillary thyroid carcinoma and the clinical significance thereof].
He F; Li H; Li WS; Dong XH
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(6):393-6. PubMed ID: 19567117
[TBL] [Abstract][Full Text] [Related]
13. Altered chemokine receptor expression in papillary thyroid cancer.
González HE; Leiva A; Tobar H; Böhmwald K; Tapia G; Torres J; Mosso LM; Bueno SM; Gonzalez P; Kalergis AM; Riedel CA
Thyroid; 2009 Sep; 19(9):957-65. PubMed ID: 19731977
[TBL] [Abstract][Full Text] [Related]
14. Level IIb lymph node metastasis in neck dissection for papillary thyroid carcinoma.
Lee BJ; Wang SG; Lee JC; Son SM; Kim IJ; Kim YK
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1028-30. PubMed ID: 17938327
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications.
Omar E; Madhavan M; Othman NH
Pathology; 2004 Apr; 36(2):152-9. PubMed ID: 15203751
[TBL] [Abstract][Full Text] [Related]
16. Expression of cell cycle biomarkers and telomere length in papillary thyroid carcinoma: a comparative study between radiation-associated and spontaneous cancers.
Achille M; Boukheris H; Caillou B; Talbot M; de Vathaire F; Sabatier L; Desmaze C; Schlumberger M; Soria JC
Am J Clin Oncol; 2009 Feb; 32(1):1-8. PubMed ID: 19194115
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma.
Koo BS; Choi EC; Yoon YH; Kim DH; Kim EH; Lim YC
Ann Surg; 2009 May; 249(5):840-4. PubMed ID: 19387316
[TBL] [Abstract][Full Text] [Related]
18. Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size.
Cvejic DS; Savin SB; Petrovic IM; Paunovic IR; Tatic SB; Havelka MJ
Head Neck; 2005 Dec; 27(12):1049-55. PubMed ID: 16155918
[TBL] [Abstract][Full Text] [Related]
19. Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer.
Cheng S; Liu W; Mercado M; Ezzat S; Asa SL
Endocr Relat Cancer; 2009 Jun; 16(2):455-66. PubMed ID: 19261683
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma.
Kaseta MK; Khaldi L; Gomatos IP; Tzagarakis GP; Alevizos L; Leandros E; Papagelopoulos PJ; Soucacos PN
J Surg Oncol; 2008 Mar; 97(3):259-66. PubMed ID: 18161867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
